DK2178881T3 - Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere - Google Patents

Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere

Info

Publication number
DK2178881T3
DK2178881T3 DK08845285T DK08845285T DK2178881T3 DK 2178881 T3 DK2178881 T3 DK 2178881T3 DK 08845285 T DK08845285 T DK 08845285T DK 08845285 T DK08845285 T DK 08845285T DK 2178881 T3 DK2178881 T3 DK 2178881T3
Authority
DK
Denmark
Prior art keywords
pharmaceuticals
same
triazolopyridazine
medicinals
benzothiazol
Prior art date
Application number
DK08845285T
Other languages
Danish (da)
English (en)
Inventor
Eva Albert
Eric Bacque
Conception Nemecek
Antonio Ugolini
Sylvie Wentzler
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2178881(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0705789A external-priority patent/FR2919870B1/fr
Priority claimed from FR0801819A external-priority patent/FR2929613B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2178881T3 publication Critical patent/DK2178881T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK08845285T 2007-08-09 2008-08-06 Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere DK2178881T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705789A FR2919870B1 (fr) 2007-08-09 2007-08-09 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR0801819A FR2929613B1 (fr) 2008-04-02 2008-04-02 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
PCT/FR2008/001172 WO2009056692A2 (fr) 2007-08-09 2008-08-06 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
DK2178881T3 true DK2178881T3 (da) 2014-01-13

Family

ID=40524792

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08845285T DK2178881T3 (da) 2007-08-09 2008-08-06 Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere

Country Status (41)

Country Link
US (3) US8546393B2 (enExample)
EP (1) EP2178881B1 (enExample)
JP (1) JP5694767B2 (enExample)
KR (1) KR101654376B1 (enExample)
CN (1) CN101801973B (enExample)
AR (1) AR068055A1 (enExample)
AU (1) AU2008320791B2 (enExample)
BR (1) BRPI0815606A2 (enExample)
CA (2) CA2884102A1 (enExample)
CL (1) CL2008002351A1 (enExample)
CO (1) CO6251270A2 (enExample)
CR (1) CR11252A (enExample)
CY (1) CY1114906T1 (enExample)
DK (1) DK2178881T3 (enExample)
DO (1) DOP2010000040A (enExample)
EA (1) EA023465B1 (enExample)
EC (1) ECSP109944A (enExample)
ES (1) ES2436657T3 (enExample)
GT (1) GT201000023A (enExample)
HR (1) HRP20131182T1 (enExample)
IL (1) IL203734A (enExample)
JO (1) JO2935B1 (enExample)
MA (1) MA31685B1 (enExample)
ME (1) ME00972B (enExample)
MX (2) MX340060B (enExample)
MY (1) MY152535A (enExample)
NI (1) NI201000022A (enExample)
NZ (1) NZ583177A (enExample)
PA (1) PA8792501A1 (enExample)
PE (1) PE20090900A1 (enExample)
PL (1) PL2178881T3 (enExample)
PT (1) PT2178881E (enExample)
RS (1) RS53078B (enExample)
SG (1) SG183077A1 (enExample)
SI (1) SI2178881T1 (enExample)
TN (1) TN2010000026A1 (enExample)
TW (1) TWI429649B (enExample)
UA (1) UA101328C2 (enExample)
UY (1) UY31277A1 (enExample)
WO (1) WO2009056692A2 (enExample)
ZA (1) ZA201000912B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AU2009272517A1 (en) * 2008-07-18 2010-01-21 Sanofi-Aventis Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as MET inhibitors
WO2010007316A2 (fr) * 2008-07-18 2010-01-21 Sanofi-Aventis NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EP2396333B1 (en) * 2009-02-10 2013-07-03 AstraZeneca AB Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
UY32623A (es) * 2009-05-11 2010-12-31 Astrazeneca Ab Derivados bicíclicos para afecciones asociadas al receptor de andrógenos
MX336996B (es) 2009-12-31 2016-02-09 Hutchison Medipharma Ltd Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
FR2958292A1 (fr) * 2010-03-30 2011-10-07 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
TW201202242A (en) 2010-03-30 2012-01-16 Sanofi Aventis 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン
EP2872119A1 (en) * 2012-07-12 2015-05-20 Sanofi Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2014076162A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10047071B1 (en) 2018-01-15 2018-08-14 King Saud University Dihydropyrimidinone derivatives
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110041311B (zh) * 2019-05-20 2021-03-19 东南大学 一种荧光探针分子ml-fp及其制备方法和应用
WO2020251911A1 (en) * 2019-06-12 2020-12-17 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499995A1 (fr) 1981-02-13 1982-08-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
NZ568807A (en) * 2005-12-21 2011-05-27 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008051808A2 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Also Published As

Publication number Publication date
EP2178881A2 (fr) 2010-04-28
CN101801973A (zh) 2010-08-11
US20100298315A1 (en) 2010-11-25
NZ583177A (en) 2012-03-30
KR20100065319A (ko) 2010-06-16
JP5694767B2 (ja) 2015-04-01
KR101654376B1 (ko) 2016-09-05
PT2178881E (pt) 2013-12-26
ME00972B (me) 2012-06-20
JO2935B1 (en) 2016-03-15
WO2009056692A3 (fr) 2009-06-25
TWI429649B (zh) 2014-03-11
CA2695628C (fr) 2016-11-22
CA2695628A1 (fr) 2009-05-07
UY31277A1 (es) 2009-03-31
JP2010535747A (ja) 2010-11-25
SI2178881T1 (sl) 2014-01-31
PL2178881T3 (pl) 2014-03-31
AU2008320791B2 (en) 2013-10-10
TN2010000026A1 (fr) 2011-09-26
SG183077A1 (en) 2012-08-30
AU2008320791A1 (en) 2009-05-07
HRP20131182T1 (hr) 2014-01-17
ES2436657T3 (es) 2014-01-03
US9115134B2 (en) 2015-08-25
EA023465B1 (ru) 2016-06-30
IL203734A (en) 2014-12-31
MX340060B (es) 2016-06-23
PE20090900A1 (es) 2009-08-06
CO6251270A2 (es) 2011-02-21
CR11252A (es) 2010-06-21
ZA201000912B (en) 2011-04-28
MY152535A (en) 2014-10-15
WO2009056692A2 (fr) 2009-05-07
US20150344484A1 (en) 2015-12-03
US9321777B2 (en) 2016-04-26
NI201000022A (es) 2010-03-11
DOP2010000040A (es) 2010-03-31
MA31685B1 (fr) 2010-09-01
EP2178881B1 (fr) 2013-10-02
GT201000023A (es) 2012-04-03
BRPI0815606A2 (pt) 2015-03-03
UA101328C2 (uk) 2013-03-25
RS53078B (sr) 2014-06-30
CL2008002351A1 (es) 2009-10-23
PA8792501A1 (es) 2009-04-23
CN101801973B (zh) 2014-03-12
TW200911816A (en) 2009-03-16
EA201070235A1 (ru) 2010-08-30
AR068055A1 (es) 2009-11-04
CA2884102A1 (fr) 2009-05-07
CY1114906T1 (el) 2016-12-14
ECSP109944A (es) 2010-03-31
US20140005189A1 (en) 2014-01-02
MX2010001593A (es) 2010-10-04
US8546393B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
DK2178881T3 (da) Hidtil ukendte 6-triazolopyridazin-sulfanyl-benzothiazol- og -benzimidazolderivater, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler og farmaceutiske sammensætninger og hidtil ukendt anvendelse som met-hæmmere
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
DK2040702T3 (da) Anvendelse af AMPK-aktiverende imidazolderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater omfattende dem
IL192440A0 (en) Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
DK1730131T3 (da) Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
DK2413912T3 (da) Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
IL192442A0 (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
DK2158194T3 (da) Derivater af 7-alkynyl-1,8-naphtyridoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
DK1940703T3 (da) Anordning til emballering og udlevering af faste formede legemer, specielet til orale tabletter og/eller kapsler
DK2231598T3 (da) Nye diazeniumdiolatderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2268644T3 (da) Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
DK2240487T3 (da) Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
DK2094699T3 (da) Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7
DK2061807T3 (da) MHC-oligomerer, bestanddele deraf og fremgangsmåder til fremstilling deraf
DK2147915T3 (da) Nye cycloalkylerede benzothiadiazinderivater, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1838315T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til fremstilling heraf, deres anvendelse som medikament samt medikamenter indeholdende dem
DK1718340T3 (da) Nye effektorkonjugater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse